

# BIOINFORMANT

## Mesenchymal Stem Cells, Advances & Applications



1ST AND ONLY MARKET RESEARCH FIRM TO  
SPECIALIZE IN THE STEM CELL INDUSTRY

## **TABLE OF CONTENTS**

1.	REPORT OVERVIEW	20
1.1	Statement of the Report	22
1.2	Target Demographic	24
1.3	Report Sources	24
1.4	Purpose of the Report	24
1.4.1	Survey Recent MSC Advancements	25
1.4.3	Assess Opportunities for Commercialization	25
1.4.4	Identify Major Market Players & Assess the Competitive Environment	25
1.4.5	Identify Existing and Emerging Trends	26
1.4.6	Identify Critical Opportunities and Threats within the MSC Market	26
1.5	Executive Summary	27
1.6	Introduction	28
2.	MESENCHYMAL STEM CELLS (MSCS): AN OVERVIEW	30
2.1	Stabilization of hMSCs as a Technology	30
2.2	The Impact of MSCs on Regenerative Medicine	31
2.3	Timeline of MSC Nomenclature	31
2.4	Sources of MSCs	32
2.4.1	Bone Marrow-Derived MSCs (BM-MSCs)	33
2.4.2	Adipose-Derived MSCs (AD-MSCs)	34
2.4.3	Umbilical Cord-Derived MSCs	34
2.5	Cell Surface Markers in MSCs	35
2.6	In Vitro Differentiation Potentials of MSCs	36
2.7	Soluble Factors Secreted by MSCs	37
2.8	Stemness Genes Present in MSCs	38
3.	PUBLISHED SCIENTIFIC PAPERS ON MSCS	40
3.1	Number of Papers on MSCs & iPSCs Compared	41
3.2	Number of Papers Published on MSC-based Clinical Trials	43
3.3	Number of Papers on Clinical Trials using MSCs for Specific Diseases	44
3.4	Published Papers on Modified MSCs	46
3.5	Published Papers on MSC-Derived Exosomes	47
4.	STEM CELLS PATENT LANDSCAPE: AN OVERVIEW	49
4.1	Geographical Distribution of Stem Cell Patent Filing	50
4.1.1	Leading Players in Stem Cell Patent Arena	51
4.1.2	Types of Patent Document Holders in Stem Cell Arena	52
4.1.3	Top Ten Stem Cell Patent Owners by Size of Patent Portfolio	52
4.2	MSC Patents	53
4.2.1	Top Ten MSC Patent Applicants	54
4.2.2	Status of MSC Patent Applications	55
4.2.3	MSC Patent Jurisdictions	56
4.2.4	Top Ten MSC Patent Inventors	56
4.2.5	Top Ten MSC Patent Owners	57
4.2.6	Patent Landscape of MSC-Derived Exosomes	57
4.2.7	Number of Patent Applications by Year	58
4.2.8	MSC-Exosomes Patent Jurisdiction	59
4.2.9	Top Ten Patent Inventors	59

5.	MSCS: CLINICAL TRIAL LANDSCAPE	60
5.1	Analysis of Data from ClinicalTrials.gov	60
5.1.1	Sources of MSCs for Clinical Trials	62
5.1.2	Autologous vs. Allogeneic MSCs in Clinical Studies	63
5.1.3	Types of Funding for MSC-based Clinical Trials	64
5.1.4	Types of MSC-based Clinical Trials	65
5.1.5	MSC-based Clinical Trials by Phase of Development	66
5.2	Administration of MSCs in Clinical Trials	67
5.3	MSC Clinical Trials by Disease Category	67
5.3.1	MSC-based Clinical Trials for Musculoskeletal Disorders	68
5.3.2	MSC-based Clinical Trials for Neurological Disorders	69
5.3.3	Clinical Trials involving MSC-derived Exosomes	70
6.	BIOENGINEERING SOLUTIONS TO BOOST MSC'S FUNCTIONS	73
6.1	Small-Molecule Priming	73
6.2	Particle Engineering	74
6.3	Genetic Engineering	74
6.3.1	Engineering MSCs to Go Beyond their Innate Functions	75
6.3.2	Engineered MSCs for Neurological Conditions	76
6.3.3	Engineered MSCs for Cardiovascular Diseases	77
6.3.4	Engineered MSCs for Lung Injury	77
6.3.5	Engineered MSCs for Diabetes	78
6.4	Bioengineering Approaches to Improve MSC Administration	78
7.	MANUFACTURING OF MSCS	80
7.1	Autologous and Allogeneic MSCs	80
7.2	Methods of Isolation of MSCs	81
7.3	Cell Expansion: Conventional Cultures to Bioreactors	82
7.3.1	Monolayer Culture Systems	82
7.3.2	Bioreactor-Based Cell Expansion	83
7.3.2.1	Stirred Tank Bioreactor	83
7.3.2.2	Rocking Bioreactor	84
7.3.2.3	Hollow Fiber Bioreactors	84
7.3.2.4	Fixed-Bed Bioreactors	85
7.4	Bioreactors in Current Use	86
7.4.1	Miniaturized Bioreactors	86
7.4.2	Alternative Mixing Mechanisms	86
7.5	Main Features of Commercial Bioreactors	91
7.6	Number of Cells per Batch by Technologies	93
7.7	Microcarriers for the Expansion of MSCs	93
7.8	Downstream Processing of MSCs	96
7.8.1	Cell Detachment and Separation	96
7.8.2	Cell Washing and Concentration	97
7.8.3	Safety & Potency Assays	97
7.8.4	Surface Markers for Identification during MSC Manufacture	98
7.9	Autologous & Allogeneic MSC Manufacturing: A Comparison	99
7.9.1	Manufacturing Cost: Autologous and Allogeneic MSCs	100
7.9.2	Cost of Manufacturing Autologous MSCs	101
7.9.3	Cost of Donor Screening & Testing	101
7.9.4	Cost for Release Testing	102
7.10	Cost Breakdown in MSC Manufacturing	102
7.10.1	Strategies for Cost Reduction	103
7.10.1.1	Cost of Manufacture in Partial Automation vs. Full Automation	104

7.10.1.2	CoG Breakdown in Partially-Automated MSC Manufacturing	104
7.10.1.3	CoG Breakdown in Fully Automated MSC Manufacturing	105
7.10.1.4	Higher Throughput in Partially Automated Facilities	106
8.	SMALL SCALE PROCESSING OF MSCS	108
8.1	Model Design	108
8.2	Culture Media	109
9.	LARGE-SCALE MANUFACTURING OF MSCS	114
9.1	The Four Common Bioprocessing Strategies for Large-Scale Expansion of MSCs	115
9.2	Commonly Used Sources of MSCs for Large-Scale Expansion	116
9.3	Commonly used Culture Media for Large-Scale Expansion of MSCs	117
9.3.1	Expansion Ratios Achieved with Different Culture Media	117
9.4	Comparison between the Four Large-Scale MSC Expansion Strategies	119
10.	CONTRACT MANUFACTURING FOR CELL & GENE THERAPIES	120
10.1	The Need for Staff with Expertise	120
10.2	Capacity Constraints	120
10.3	CDMO Platforms Showing Greatest Growth Potential	121
10.4	Outsourcing Trends for Cell & Gene Therapies (CGT)	121
10.4.1	Number of CDMOS Utilized by Biotechs	122
10.5	CMOs/CDMOs	122
10.5.1	Contract Manufacturing Organizations (CMOs)	123
10.5.1.1	Major Services offered by CMOs	123
10.5.2	Contract Development and Manufacturing Organizations (CDMOs)	124
10.6	Global Bioprocessing Capacity	124
10.6.1	Capacity Growth over Time	124
10.6.2	Current Distribution of Capacity by Facility Size	126
10.6.3	Global Bioprocessing Capacity by Region	126
10.7	Top Global CDMOs in 2022	128
10.7.1	Major Cell & Gene Therapy CDMOs in the U.S	128
10.7.2	Major Cell & Gene Therapy Contract Manufacturers in Europe	129
10.8	U.K.'s Domination in European Cell & Gene Therapy Contract Manufacturing	130
10.8.1	Cell & Gene Therapy GMP Manufacturing in U.K.	130
10.8.2	U.K. Cleanroom Footprint for CGT Manufacturing, 20018-2022	131
10.8.3	Cell Therapy Process Capabilities in the U.K. by Types of Process	132
10.8.4	Gene Therapy Process Capabilities in the U.K. by Types of Process	133
10.8.5	Countries Importing Cell & Gene Therapy Services from U.K.	134
11.	MAJOR DISEASES ADDRESSED BY MSCS	136
11.1	Studies using MSCs for Autoimmune Diseases	136
11.2	Studies using MSCs for Cardiovascular Diseases	137
11.3	Studies using MSCs for Neurodegenerative Diseases	138
11.4	Studies using MSCs for Bone & Cartilage Diseases	139
11.5	Studies using MSCs in GvHD	140
11.6	Studies using MSCs in Crohn's Disease	141
11.7	Studies using MSCs in Type 1 Diabetes	142
11.8	Studies using MSCS in Systemic Lupus Erythematosus (SLE)	142
11.9	Studies using MSCs in Parkinson's disease (PD)	143
11.10	Studies using MSCs in Alzheimer's Disease (AD)	143
11.11	Studies using MSCs in Kidney Failure	144
11.12	Studies using MSCs in Spinal Cord Injury (SCI)	144

11.13	MSCs for Chronic Wounds	145
12.	CURRENT STATUS OF MESENCHYMAL STEM CELL INDUSTRY	146
12.1	Brief Account of Modified MSCs	146
12.1.1	Genetic Modification of MSCs	147
12.1.2	Priming of MSCs	148
12.1.2.1	Primed MSCs in Clinical Trials	148
12.1.3	Biomaterial Strategies	149
12.1.4	MSC Secretomes	150
12.1.5	MSCs in Topical Cosmetics	151
12.1.5.1	Cosmetic Effects of Secretomes	151
12.1.5.2	Secretome-Based Formulations for Skincare	152
12.2	MSC-Based Products with Marketing Approval	155
12.2.1	Alofisel	156
12.2.2	Stemirac	157
12.2.3	Stempeucel	157
12.2.4	Temcell HS	158
12.2.5	Neuronata-R	158
12.2.6	Prochymal	158
12.2.7	Cupistem	159
12.2.8	Cartistem	159
12.2.9	Cellgram-AMI	159
12.2.10	Queencell	159
12.3	Currently Marketed MSC-Based Bone Matrices	160
12.3.1	Osteocel	161
12.3.2	AlloStem	161
12.3.3	Cellentra VCBM	161
12.3.4	HiQCell	162
12.3.5	Trinity ELITE	162
12.3.6	Map3	162
12.3.7	Trinity Evolution	163
12.3.8	Carticel	163
12.3.9	Chondron	163
12.3.10	DeNovo	163
12.3.11	Chondrocelect	164
12.3.12	Ossron	164
12.3.13	JACC	164
12.3.14	MACI	165
12.3.15	Ortho-ACI	165
12.3.16	Spherox	165
12.3.17	Ossgrow	166
12.3.18	Cartigrow	166
12.3.19	ViviGen	166
12.3.20	Bio4	166
12.3.21	Cartiform	167
13.	RECENT COLLABORATIONS IN MSC SECTOR	168
13.1	RoosterBio's Partnership with AGC Biologics	168
13.2	RoosterBio's Partnership with ShiftBio	168
13.3	Pluristem's Collaboration with Tnuva Group	169
13.4	RoosterBio's Partnership with Univercells Technologies	169
13.5	Partnership between Cynata & Fujifilm	169
13.6	Collaboration between American CryoStem Corp. & BioTherapeutic Labs Corp	170
13.7	RoosterBio's Partnership with Sartorius	170

13.8	Research & Development Agreement between American CryoStem and CRADA	171
13.9	RoosterBio's Partnership with Sartorius Korea Biotech	171
13.10	Partnership between Catalent and BrainStorm	172
13.11	Collaboration between Cipla & Stempeutics	172
13.12	Aethlon's Collaboration with University of Pittsburgh	172
13.13	RoosterBio's Partnership with Senti Biosciences	173
14.	MARKET ANALYSIS	174
14.2	Price Tags of MSC-Based CT Treatment	175
14.3	Price Tags of MSC-Based Matrices	177
14.4	Market Size of MSC-Based Therapies	178
14.5	Global Market for MSC-Based Therapeutics	179
14.6	Global Demand for Mesenchymal Stem Cells (MSCs)	181
14.6.1	Global Demand for MSCs in Academic and Preclinical Studies	181
14.6.2	Global Demand for MSCs in Clinical Trials	181
14.6.3	Global Demand for MSCs for the Development of Therapeutics	181
14.6.4	Global Demand for MSCs to Develop Exosome Products	182
14.6.5	Global Market for MSCs in Emerging Industries	182
14.6.6	Global Market for MSCs	182
14.6.7	Market Share of MSC-Based Business Segments	184
15.	COMPANY PROFILES	186
15.1	101 Bio	186
15.1.2	Products	186
15.1.3	Services	187
15.2	AbbVie, Inc.	188
15.2.1	SkinMedica Neck Correct Cream	188
15.3	Abzena	189
15.3.1	Services	189
15.4	Adipomics, Inc.	190
15.5	Advancells	191
15.5.1	MSC-Derived Exosome Therapy	191
15.6	Advent BioServices, Ltd.	192
15.6.1	Ultra Cold Storage Services	192
15.6.2	Quality Control Services	192
15.7	Aegle Therapeutics	193
15.7.1	Aegle's Platform Technology	193
15.7.2	Epidermolysis Bullosa	193
15.8	Aethlon Medical, Inc.	194
15.8.1	Hemopurifier in Infectious Disease	194
15.8.2	Status of Clinical Studies	195
15.8.3	Hemopurifier in Cancer	195
15.9	AGC Biologics	196
15.9.1	Offerings	196
15.10	AgeX Therapeutics, Inc.	197
15.10.1	Pluristem Technology	197
15.10.2	Induced Tissue Generation	197
15.10.3	UniverCyte	198
15.10.4	HyStem Delivery Technology	198
15.11	AlloSource, Inc.	199
15.11.1	Allografts with Tissue-derived MSCs	199
15.11.2	Products	199
15.11.2.1	AlloConnex	199
15.11.2.2	AlloFuse & AlloFuse Plus DBM	200

15.11.2.3	AlloFlex Plus	200	
15.11.2.4	AlloFuse Cervical Grafts	200	
15.11.2.5	AlloFuse Fiber and Fiber Boats	201	
15.11.2.6	AlloFuse Select CM	201	
15.12	Ambulero	202	
15.12.1	Supercharged MSCs	202	
15.12.2	Ambulero's Pipeline	202	
15.13	American CryoStem Corporation	203	
15.13.1	Products	203	
15.13.1.1	CELLECT Tissue Harvesting System	203	
15.13.1.2	ACSelerateMAX hMSC Medium	203	
15.13.1.3	ATCELL Mesenchymal Stem Cells (ADSCs)	204	
15.13.2	Services	204	
15.13.2.1	ATGRAFT Fat Storage	204	
15.13.2.2	Adult Stem Cell Program	204	
15.14	American Type Culture Collection (ATCC)	205	
15.14.1	Stem Cell Products	205	
15.15	AMS Biotechnology, Ltd. (AMSBIO)	206	
15.15.1	Products	206	
15.16	Andelyn Biosciences	207	
15.16.1	Andelyn's Solutions	207	
15.17	Anemocyte S.r.l	208	
15.17.1	Total GMP Capacity	208	
15.17.2	Product Types	208	
15.17.3	Manufacturing Services	208	
15.18	Anterogen, Co., Ltd.	209	
15.18.1	Products	209	
15.18.1.1	Cupistem Injection	209	
15.18.1.2	Queencell Injection	210	
15.19	AQ Skin Solutions	210	
15.19.1	Products	210	
15.19.1.1	AQ Active Serum	210	
15.19.1.2	AQ Eye Serum	211	
15.19.1.3	AQ Lash	211	
15.19.1.4	AQ Vaginal Rejuvenation System	211	
15.20	Arranta Bio	212	
15.20.1	Services	212	
15.21	Aruna Bio	213	
15.21.1	AB126	213	
15.22	Avid Bioservices, Inc.	214	
15.22.1	Services	214	
15.23	Bacthera	215	
15.23.1	Services	215	
15.24	Baylx, Inc.	216	
15.24.1	Technology	216	
15.24.2	Rheumatoid Arthritis	216	
15.24.3	Metastatic Cancer	216	
15.24.4	FDA Clearance of IND Application	217	
15.25	BioCardia	218	
15.25.1	BioCardia's Pipeline Overview	218	
15.25.1.1	CardiAMP Cell Therapy	218	
15.25.1.2	CardiALLO Cell Therapy	219	
15.26	BioCentriq	220	
15.26.1	Clinical Manufacturing Services	220	
15.26.2	Process Development Services	220	
15.27	BioEden, Inc.	221	

15.28	Bioinova s.r.o	221
15.28.1	MSCs for Clinical Trials	221
15.28.2	Novel Solution for Storage and Transportation of Cells	222
15.29	BioRestorative Therapies	223
15.29.1	BRTX-100	223
15.29.2	ThermoStem	223
15.30	Bioscience Institute S.p.A	224
15.30.1	LIPOSKILL	224
15.30.2	HAIRSKILL	224
15.30.3	GYNSKILL	224
15.30.4	LIPOSKILL PLUS	225
15.31	Bio-Techne	225
15.31.1	Mesenchymal Stem Cell Products	225
15.32	Blue Horizon International, LLC	226
15.32.1	BHI's Stem Cell Division	226
15.33	Boehringer Ingelheim BioXcellence	227
15.33.1	Services	227
15.33.2	Cell Line Development Services	227
15.34	Bonus Biogroup, Ltd.	228
15.34.1	BonoFill	228
15.34.2	MesenCure	228
15.35	BrainStorm Cell Therapeutics	229
15.35.1	MSC-NTF Cells	229
15.36	Caregen Nordic	230
15.36.1	Dermaheal HSR	230
15.36.2	Dermaheal HL	230
15.36.3	Dermaheal SB	231
15.36.4	Dermaheal Stem C'rum	231
15.36.5	Dermaheal Stem C'rum SR	231
15.37	CardioCell, LLC	232
15.37.1	The itMSC Advantage	232
15.37.2	Clinical Trials	232
15.38	Catalent Pharma Solutions	233
15.38.1	OneBio Integrated Suite	233
15.38.2	Gene Therapy Services	233
15.38.3	Cell Therapy Services	234
15.39	CCRM	234
15.39.1	CDMO Services	234
15.40	Cellipont Bioservices	235
15.40.1	Cellipont's Capabilities	235
15.40.2	Cellipont's Cell Expertise	236
15.41	Celprogen, Inc.	237
15.41.1	Products	237
15.41.1.1	FolliStem	237
15.41.1.2	FolliStem Jawan	237
15.42	CellResearch Corporation, Pte Ltd.	238
15.42.1	Umbilical Cord Lining Stem Cells	238
15.43	Celltix Therapeutics Corporation	239
15.43.1	Therapy Services	239
15.44	Cellular Biomedicine Group, Inc.	240
15.45	Citius Pharmaceuticals, Inc.	241
15.45.1	Stem Cell Platform	241
15.46	Charles River Laboratories International, Inc.	242
15.46.1	Products & Services	242
15.47	Corestem, Inc.	243
15.47.1	ALS (NeuroNata-R)	243



15.48	Creative Bioarray	244
15.48.1	MSC Services	244
15.48.1.1	MSC Isolation and Expansion Services	244
15.48.1.2	MSC Characterization Service	245
15.48.1.3	MSC Differentiation Service	245
15.49	Curia Global, Inc.	246
15.49.1	Services	246
15.50	Cynata Therapeutics, Ltd.	247
15.50.1	Cymerus Platform	247
15.50.1.1	Importance of Cymerus Technology	247
15.50.2	Preclinical Development	248
15.50.2.1	GvHD	248
15.50.2.2	Critical Limb Ischemia	248
15.50.2.3	Asthma	248
15.50.2.4	Heart Attack	249
15.50.2.5	Diabetic Wounds	249
15.50.2.6	Coronary Artery Disease (CAD)	249
15.50.2.7	Acute Respiratory Distress Syndrome (ARDS)	249
15.50.2.8	Sepsis	250
15.50.2.9	Osteoarthritis	250
15.51	Cytovance Biologics	251
15.51.1	CGMP Manufacturing	251
15.52	Dendreon	252
15.52.1	Provenge Immunotherapy	252
15.52.2	Services	252
15.53	Direct Biologics	253
15.53.1	ExoFlo	253
15.54	ElevateBio	254
15.54.1	ElevateBio's Enabling Technologies	254
15.54.2	BaseCamp cGMP	255
15.55	Exothera	256
15.55.1	Exoscan Process Analysis Services	256
15.55.2	Process Design & Development Services	256
15.55.3	GMP Manufacturing Services	257
15.56	EXOSOMEplus	258
15.57	FUJIFILM Cellular Dynamics, Inc.	259
15.57.1	iCell Mesenchymal Stem Cells	259
15.58	Fujifilm Diosynth Biotechnologies	260
15.58.1	Cell & Gene Therapy Services	260
15.59	Future Cell Japan Co., Ltd.	261
15.59.1	BABY STEM	261
15.60	Genezen	262
15.60.1	Genezen's Capabilities	262
15.61	Hope Biosciences, LLC	264
15.61.1	Adult Stem Cell Banking	264
15.61.2	Newborn Stem Cell Banking	264
15.61.3	Hope Sponsored Clinical Trials	264
15.62	Invitrx Therapeutics	266
15.62.1	Reluma	266
15.63	JCR Pharmaceuticals, Co., Ltd.	267
15.63.1	TEMCELL HS Inj.	267
15.64	Just-Evotec Biologics, Inc.	268
15.64.1	J.POD Biomanufacturing Facility	268
15.64.2	J.Design Solutions	268
15.64.3	J.DISCOVERY – Molecule Discovery	268
15.64.4	J.MD – Molecule Design	269

15.64.5	JP3 – Process & Product Design	269
15.64.6	J-POD – Manufacturing Design	269
15.65	Kimera Labs, Inc.	270
15.65.1	XoGlo	270
15.65.2	XoGlo Pro	270
15.65.3	Equisome HC	272
15.65.4	Vive	272
15.65.4.1	Effects of MSC Exosomes on Skin	272
15.66	LifeCell	273
15.66.1	Large-Scale Manufacturing of MSCs	273
15.67	Longeveron	274
15.67.1	Lomecel-B	274
15.67.2	Focused Therapeutic Areas	274
15.67.2.1	Hypoplastic Left Heart Syndrome (HLHS) Research Program	275
15.67.2.2	Alzheimer’s disease (AD) Research Program	275
15.67.2.3	Aging Frailty Research Program	275
15.67.2.4	Metabolic Syndrome Research Program	275
15.67.2.5	Acute Respiratory Distress Syndrome (ARDS) Research Program	276
15.68	Lonza Group, Ltd.	277
15.68.1	Product Overview	277
15.68.1.1	Poietics	277
15.68.1.2	MSCGM Growth Medium	278
15.68.1.3	TheraPEAK Growth Medium	278
15.68.1.4	hMSC Chondrogenic Differentiation Medium	278
15.68.1.5	hMSC Adipogenic Differentiation Medium	278
15.68.1.6	ReagentPack Subculture Reagents	279
15.68.1.7	Trypsin/EDTA for Mesenchymal Stem Cells	279
15.69	Lorem Cytori USA, Inc.	280
15.69.1	Celution System	280
15.70	Lykan Bioscience	281
15.70.1	Process Development	281
15.70.2	Analytical Development	281
15.70.3	Manufacturing Science & Technology	282
15.70.4	Clinical & Commercial Manufacturing	282
15.70.5	Supply Chain & Logistics	283
15.70.6	Quality & Compliance	283
15.71	Matica Biotechnology, Inc.	284
15.71.1	Cell Line Development Services	284
15.71.2	Process Development Services	284
15.71.3	Assay Development Services	284
15.71.4	GMP Production Services	285
15.71.5	Product Release & Stability Testing	285
15.72	Medipost, Co., Ltd.	286
15.72.1	Products	286
15.72.1.1	Cartistem	286
15.72.1.2	Pneumostem	286
15.72.1.3	SMUP-IA-01	287
15.72.1.4	SMUP-IV-01	287
15.73	Mesoblast, Ltd.	288
15.73.1	Product Candidates	288
15.73.1.1	Remestemcel-L	289
15.73.1.2	Rexlemestrocel-L	289
15.74	MilliporeSigma	290
15.74.1	Cell Culture & Analysis Products	290
15.75	NecstGen	292
15.75.1	Cell Therapy Development & Manufacturing	292

15.75.2	Viral Vector Development & Manufacturing	293
15.75.3	Cleanroom Rental	293
15.76	Novus Biologicals, LLC	294
15.77	NuVasive, Inc.	295
15.77.1	Osteocel Family	295
15.78	OCT Therapies & Research Pvt. Ltd.	296
15.79	Orthofix Medical, Inc.	297
15.79.1	Trinity ELITE	297
15.79.2	TrinityEvolution	297
15.80	Personal Cell Sciences, Corp.	298
15.80.1	Autokine CM	298
15.80.2	Products	298
15.80.2.1	U Autologous Adult Stem Cell Regenerative Firming Serum	298
15.80.2.2	U Autologous Adult Stem Cell Regenerative Eye Cream	299
15.80.2.3	U Autologous Adult Stem Cell Regenerative Moisturizer	299
15.81	Personalized Stem Cells, Inc.	300
15.81.1	Personalized Stem Cell Study: Knee Osteoarthritis	300
15.82	Porton Advanced	301
15.82.1	Cell Therapy Services	301
15.82.2	Portons LVV Services	301
15.83	Pluristem Therapeutics, Inc.	302
15.83.1	PLX Products	302
15.83.2	PLX-PAD	303
15.83.2.1	Mechanism of Action	303
15.83.3	PLX-R18	303
15.83.3.1	Mechanism of Action	304
15.83.4	PLX-Immune	304
15.83.4.1	Mechanism of Action	304
15.84	PromoCell GmbH	305
15.84.1	Human Stem & Blood Cell Culture Products	305
15.85	Regeneus, Ltd.	306
15.85.1	Technologies	306
15.85.1.1	Progenza	306
15.85.1.1.1	Mechanism of Action	306
15.85.1.2	Sygenus	307
15.85.1.2.1	Mechanism of Action	307
15.85.2	Product Pipeline	307
15.86	Reliance Life Sciences Pvt. Ltd.	308
15.86.1	Regenerative Medicine Products	308
15.87	Rentschler Biopharma	309
15.87.1	Services	309
15.88	Resilience	310
15.88.1	Resilience's Capabilities	310
15.89	Richter-HELM	311
15.89.1	Services	311
15.90	RoosterBio, Inc.	312
15.90.1	RoosterBio's Technology	312
15.90.2	Products	312
15.90.2.1	Human Mesenchymal Stem Cells (hMSCs)	313
15.90.3	Genetic Engineering Tools	313
15.90.3.1	Genetic Engineering Media	314
15.90.3.2	Cell Culture Media & Supplements	314
15.90.4	Cell and Media Kits	315
15.90.5	MSC-derived Exosomes	316
15.90.6	cGMP CliniControl Products	316
15.90.7	Process Development Services	317

15.90.8	hMSC Analytical Services	318	
15.91	RoslinCT	319	
15.91.1	Services	319	
15.91.1.1	Process Development	319	
15.91.1.2	GMP Manufacturing	320	
15.91.1.3	Quality Control	320	
15.91.1.4	Quality & Regulations	320	
15.91.1.5	Product Storage & Logistics	320	
15.91.2	RoslinCT – Lykan Bioscience Combine	321	
15.92	Samsung Biologics	321	
15.92.1	Development Services	321	
15.92.2	Manufacturing Services	321	
15.93	Sentien Biotechnologies, Inc.	322	
15.93.1	SBI-101	322	
15.93.1.1	Prolonged Therapeutic Activity of MSCs in SBI-101	322	
15.93.1.2	Sentien's Product Pipeline	323	
15.94	Smith & Nephew plc	324	
15.94.1	Grafix	324	
15.95	STEMCELL Technologies, Inc.	325	
15.95.1	Products	325	
15.95.1.1	Mesenchymal Stem Cells (MSCs)	325	
15.95.1.2	Mesenchymal Stem and Progenitor Cell Research Products	325	
15.96	Stemedica Cell Technologies, Inc.	326	
15.96.1	BioSmart Technology	326	
15.96.2	Clinical Pipeline	327	
15.97	Stemmatters	328	
15.98	Stempeutics Research Pvt. Ltd.	329	
15.98.1	Stempeucel	329	
15.98.1.1	Process Description	329	
15.98.2	Stempeucare	330	
15.98.3	Cutisera	330	
15.98.4	Trichosera	330	
15.98.5	Perioptisera	330	
15.99	Syngene International Ltd.	331	
15.99.1	Services	331	
15.100	TaiwanBio Therapeutics, Co., Ltd.	332	
15.101	Takeda Pharmaceutical Co., Ltd.	333	
15.101.1	Alofisel (Darvadstrocel)	333	
15.102	Symbiosis Pharmaceutical Services	334	
15.102.1	Vial Filling Capability	334	
15.102.2	Drug Product Testing	334	
15.102.3	Qualified Person Release	335	
15.102.4	Clinical Labeling & Packaging	335	
15.102.5	Product Development	335	
15.103	Tempo Bioscience	336	
15.103.1	Products	336	
15.103.1.1	Human Cell Models	336	
15.103.2	Services & Alliances	336	
15.104	Thermo Fisher Scientific	337	
15.104.1	Cell Culture Services	337	
15.104.2	Cell Therapy Solutions	338	
15.105	TranstoxBio	339	
15.105.1	Products	339	
15.105.1.1	CarcinogenSAFE	339	
15.105.1.2	CardioSight	339	
15.105.1.3	HeMOTOX	340	

15.105.1.4	HepatoSight	340
15.105.1.5	NeuroSAFE	340
15.105.1.6	SkinIR System	340
15.105.1.7	TransD System	340
15.105.1.8	Human Umbilical Cord Blood Monocytes	341
15.105.1.9	Human Peripheral Blood CD34 Positive Cells	341
15.105.1.10	CD34+ Configured Cellular Platform	341
15.105.1.11	Human Mesenchymal Stem Cells	341
15.106	United Therapeutics Corporation	342
15.106.1	Genetically-Enhanced Mesenchymal Stem Cells (GEM)	342
15.107	Viralgen	343
15.107.1	Service	343
15.107.2	Viralgen's Facilities	343
15.108	VIVEbiotech	344
15.109	Waisman Biomanufacturing	345
15.109.1	GMP Cell Therapeutic Capabilities	345
15.109.2	Cell Bank Specifics	345
15.109.3	Waisman Products & Processes	346
15.110	WuXi Biologics	346
15.110.1	Manufacturing Services	346
15.111	Yapan Bio	347
15.111.1	Process Development Services	347
15.111.2	Process Characterization Services	348
15.111.3	GMP Manufacturing Services	348
15.112	Yposkesi	349
15.113	Zimmer Biomet Holdings, Inc.	350
15.113.1	Cellentra VCBM350	

## **INDEX OF FIGURES**

FIGURE 3.1: Number of Published Papers on MSCs between 2000 and 2022	41
FIGURE 3.2: Number of Papers on MSCs & iPSCs Compared	42
FIGURE 3.3: Number of Papers Published on MSC-based Clinical Trials, 2000-2022	44
FIGURE 3.4: Percent Share of Papers on Clinical Trials for Specific Diseases, 2000-2022	45
FIGURE 3.5: Number of Published Papers on Modified MSCs	47
FIGURE 3.6: Number of PubMed Papers on MSC-Exosomes	48
FIGURE 4.1: Number of Patent Documents in Stem Cell Therapies, 2011-2020	50
FIGURE 4.2: Geographical/Country Distribution of Stem Cell Patents	51
FIGURE 4.3: Types of Patent Document Holders in Stem Cell Arena	52
FIGURE 4.4: Number of MSC Patent Filings by Year, 2000-January 5, 2023	54
FIGURE 4.5: Number of MSC-Exosomes Patent Applications by Year, 2009 to Present	58
FIGURE 5.1: Number of Clinical Trials involving MSCs by Region	61
FIGURE 5.2: Sources of MSCs for Clinical Trials in 2022	62
FIGURE 5.3: Clinical Trials involving Autologous and Allogeneic MSCs in 2022	63
FIGURE 5.4: Types of Funding for MSC-based Clinical Trials	64
FIGURE 5.5: Types of MSC-based Clinical Trials	65
FIGURE 5.6: MSC-based Clinical Trials by Phase of Development	66
FIGURE 5.7: MSC Administration Routes	67
FIGURE 5.8: MSC Clinical Trials by Disease Category	68
FIGURE 6.1: Bioengineering Solutions to Boost the Functions of MSCs	73
FIGURE 6.2: Bioengineering Solutions for Improving Administration of MSCs	79
FIGURE 7.1: Advantages & Disadvantages of Autologous & Allogeneic MSCs	80
FIGURE 7.2: Monolayer Culture Systems	82
FIGURE 7.3: Stirred Tank Bioreactor	83

FIGURE 7.4: Rocking Bioreactor	84	
FIGURE 7.5: Hollow Fiber Bioreactors	85	
FIGURE 7.6: Fixed-Bed Bioreactors	85	
FIGURE 7.7: Number of Cells per Batch by Technologies	93	
FIGURE 7.8: Single-Use Harvestainer for Small Scale Application	96	
FIGURE 7.9: Single-Use Harvestainer for Large Scale Application	97	
FIGURE 7.10: Advantages & Disadvantages of Autologous and Allogeneic MSC	100	
FIGURE 7.11: Cost of Goods (CoG) in MSC Manufacturing	103	
FIGURE 7.12: Impact of Headcount on Overall CoG per Batch	104	
FIGURE 7.13: CoG Breakdown in Partially-Automated MSC Manufacturing	105	
FIGURE 7.14: CoG Breakdown in Fully Automated MSC Manufacturing	106	
FIGURE 7.15: Higher Throughput in Partially Automated Facilities	107	
FIGURE 8.1: Schematic of Sartorius' SelectT Automated Platform	112	
FIGURE 8.2: Model of a Clean Room in a Small Scale Manufacturing Facility	113	
FIGURE 9.1: Four Common Bioprocessing Strategies for Large-Scale Expansion of MSCs	116	116
FIGURE 9.2: Commonly Used Sources of MSCs for Large-Scale Expansion	116	
FIGURE 9.3: Commonly used Culture Media for Large-Scale Expansion of MSCs	117	
FIGURE 10.1: Outsourced Percent of CGT Manufacturing: Now and Five Years from Now	121	121
FIGURE 10.2: Number of CDMOs Utilized	122	
FIGURE 10.3: Major Services offered by CMOs	123	
FIGURE 10.4: Percentage of Total Biomanufacturing Capacity by Platform	125	
FIGURE 10.5: Global Bioprocessing Capacity by Region/Country	127	
FIGURE 10.6: U.K. Cleanroom Footprint for CGT Therapy Manufacturing, 2018-2022	132	
FIGURE 10.7: Cell Therapy Process Capabilities in the U.K. by Types of Process, 2022	133	
FIGURE 10.8: Gene Therapy Process Capabilities in the U.K. by Types of Process	134	
FIGURE 11.1: Major Diseases Addressed by MSCs in Clinical Trials	136	
FIGURE 11.2: Percent Share of Autoimmune Diseases Using MSCs in Clinical Trials	137	
FIGURE 11.3: Percent Share of MSCs by Source in Trials for Cardiac Diseases	138	
FIGURE 11.4: Percent Shares of Neurodegenerative Diseases in Clinical Trials using MSCs	139	139
FIGURE 11.5: % Shares of Studies using MSCs in Bone & Cartilage Diseases by Source	140	
FIGURE 12.1: The Four MSC Modification Techniques	146	
FIGURE 13.2: Priming Effects on MSCs	148	
FIGURE 14.1: Percent Share of Marketed CT, GT and TE Products	174	
FIGURE 14.2: Percent Market Share of CT Products by Indication	175	
FIGURE 14.3: Global Market for MSC-Based Therapeutics by Geography	180	
FIGURE 14.4: Global Market for MSCs by Geography, 2022-2030	183	
FIGURE 14.5: Market Share of MSCs by Business Segments	185	

## **INDEX OF TABLES**

TABLE 2.1: Timeline of MSC Nomenclature	32
TABLE 2.2: Sources of MSCs	33
TABLE 2.3: Advantages and Disadvantages of BM-MSCs	34
TABLE 2.4: Advantages and Disadvantages of AD-MSCs	34
TABLE 2.5: Advantages and Disadvantages of UC-MSCs	35
TABLE 2.6: Positive & Negative Markers in MSCs from different Sources	35
TABLE 2.7: In Vitro Differentiation Potentials of MSCs	36
TABLE 2.8: Soluble Factors Secreted by MSCs	37
TABLE 2.8: (CONTINUED)	38
TABLE 2.9: Some Typical Stemness Genes of MSCs	39
TABLE 3.1: Number of Published Papers on MSCs between 2000 to Present	40
TABLE 3.2: Number of Papers on MSCs & iPSCs Compared	42
TABLE 3.3: Number of Papers Published on MSC-based Clinical Trials, 2000 to Present	43

TABLE 3.4: Percent Share of Papers for Specific Diseases, 2000-2022	45
TABLE 3.5: Published Papers on Modified MSCs	46
TABLE 3.6: Number of PubMed Papers on MSC-Exosomes	48
TABLE 4.1: Number of Patent Documents in Stem Cell Therapies	49
TABLE 4.2: Top Ten Players in Stem Cell Patent Arena	51
TABLE 4.3: Top Ten Stem Cell Patent Owners by Size of Patent Portfolio	53
TABLE 4.4: Number of MSC Patent Filings by Year, 2000 to Present	53
TABLE 4.5: Top Ten MSC Patent Applicants	54
TABLE 4.6: Status of MSC Patent Applications, 2000-2022	55
TABLE 4.7: MSC Patent Jurisdictions	55
TABLE 4.7: (CONTINUED)	56
TABLE 4.8: Top Ten MSC Patent Inventors	56
TABLE 4.9: Top Ten MSC Patent Owners	57
TABLE 4.10: Top Ten MSC-Exosome Patent Applicants	58
TABLE 4.11: MSC-Exosomes Patent Jurisdiction	59
TABLE 4.12: Top Ten MSC-Exosome Patent Inventors	59
TABLE 5.1: Number of Clinical Trials involving MSCs by Region	61
TABLE 5.2: Sources of MSCs for Clinical Trials	62
TABLE 5.3: Clinical Trials involving Autologous and Allogeneic MSCs in 2022	63
TABLE 5.4: Types of Funding for MSC-based Clinical Trials	64
TABLE 5.5: Types of MSC-based Clinical Trials	65
TABLE 5.6: MSC-based Clinical Trials by Phase of Development	66
TABLE 5.7: Examples of MSC-based Clinical Trials for Musculoskeletal Disorders	68
TABLE 5.7: (CONTINUED)	69
TABLE 5.8: MSC-based Clinical Trials for Neurological Disorders	70
TABLE 5.9: Clinical Trials involving MSC-derived Exosomes	71
TABLE 6.1: Examples of Bioengineered MSCs as Living Drug Factories	75
TABLE 6.2: Examples of Oncology Indications being studied using MSC Trojan Horses	76
TABLE 6.3: Select Cases of Modified MSC Applications & Therapeutic Outcome	78
TABLE 7.1: Methods of Isolation of MSCs & Corresponding Culture Media	81
TABLE 7.2: A Snapshot of Commercially Available Culture Systems	87
TABLE 7.2: (CONTINUED)	88
TABLE 7.2: (CONTINUED)	89
TABLE 7.2: (CONTINUED)	90
TABLE 7.2: (CONTINUED)	91
TABLE 7.3: Main Features of Commercially Available Bioreactors	92
TABLE 7.4: Microcarriers for the Expansion of MSCs	94
TABLE 7.4: (CONTINUED)	95
TABLE 7.5: Basic Assays for MSCs	98
TABLE 7.6: Cell Surface Markers on MSCs and Fibroblasts	99
TABLE 7.7: Cost of Manufacturing Allogeneic MSCs	100
TABLE 7.8: Cost of Manufacturing Autologous MSCs	101
TABLE 7.9: Cost of Goods (CoG) in MSC Manufacturing	102
TABLE 7.10: CoG Breakdown in Partially-Automated MSC Manufacturing	105
TABLE 7.11: CoG Breakdown in Fully Automated MSC Manufacturing	106
TABLE 7.12: Higher Throughput in Partially Automated Facilities	107
TABLE 8.1: Key Processes and Cost Assumptions	109
TABLE 8.2: Quality Control Panels and Cost Assumptions	110
TABLE 8.3: Additional Supporting Labor Cost Assessments	110
TABLE 8.3: (CONTINUED)	111
TABLE 8.4: Additional Supporting Facility and Cost Assumptions	111
TABLE 8.4: (CONTINUED)	112
TABLE 9.1: Large-Scale Expansion of MSCs by Method, Cell Source and Media	114
TABLE 9.1: (CONTINUED)	115
TABLE 9.2: Expansion Ratios Achieved with Different Culture Media	118
TABLE 9.3: Comparison between the Four Large-Scale MSC Expansion Strategies	119

TABLE 10.1: Comparison of Capacity Trends, 2018-2021	125
TABLE 10.2: Current Distribution of Capacity by Facility Size	126
TABLE 10.3: Global Bioprocessing Capacity by Region/Country	127
TABLE 10.4: Top Global CDMOs	128
TABLE 10.5: GMP Capacities of U.S.-based Contract Manufacturers	129
TABLE 10.6: Major Cell & Gene Therapy Contract Manufacturers in Europe	129
TABLE 10.7: GMP Manufacturing Facilities for Cell and Gene Therapies in U.K., 2022	130
TABLE 10.7: (CONTINUED)	131
TABLE 10.8: U.K. Cleanroom Footprint for Cell & Gene Therapy Manufacturing, 20018-2022	132
TABLE 10.9: Countries Outsourcing Cell & Gene Therapy Services from U.K. by Country	135
TABLE 11.1: Select MSC-Based Clinical Trials for Autoimmune Diseases	137
TABLE 11.2: Select MSC-Based Clinical Trials for Cardiovascular Studies	138
TABLE 11.3: Select MSC-Based Studies using MSCs for Neurodegenerative Diseases	139
TABLE 11.4: Select MSC-Based Studies for Bone & Cartilage Diseases	140
TABLE 11.5: Ongoing Studies using MSCs for GvHD	141
TABLE 11.6: Examples of Ongoing Clinical Trials using MSCs for Crohn's Disease	141
TABLE 11.7: Examples of Ongoing Clinical Trials using MSCs for Type 1 Diabetes	142
TABLE 11.8: Examples of Currently Ongoing Clinical Trials using MSCs for SLE	142
TABLE 11.9: Examples of Ongoing Clinical Trials using MSCs for PD	143
TABLE 11.10: Examples of Currently Ongoing Clinical Trials using MSCs for AD	143
TABLE 11.11: Examples of Ongoing Clinical Trials using MSCs for Kidney Failure	144
TABLE 11.12: Examples of Ongoing Clinical Trials using MSCs for SCI	144
TABLE 11.13: Examples of Currently Ongoing Clinical Trials using MSCs for SCI	145
TABLE 12.1: Clinical Trials Involving Engineered MSCs	147
TABLE 12.2: Primed MSCs in Clinical Trials	149
TABLE 12.3: Scaffold-Based MSCs in Clinical Trials	149
TABLE 12.3: (CONTINUED)	150
TABLE 12.4: Clinical Trials Involving MSC-Derived Exosomes	151
TABLE 12.5: Commercially Available Products Incorporated with Secretomes	152
TABLE 12.5: (CONTINUED)	153
TABLE 12.5: (CONTINUED)	154
TABLE 12.6: MSC Products with Marketing Approval	155
TABLE 12.6: (CONTINUED)	156
TABLE 12.7: Marketed MSC-Containing Bone Matrices	160
TABLE 14.1: Price Tags of MSC-Based Approved CT Products	176
TABLE 14.2: Price Tags of Select MSC Progenitor-Based Products	177
TABLE 14.3: Global Market for MSC-Based Therapeutics	180
TABLE 14.4: Global Market for MSCs by Geography, 2022-2030	183
TABLE 15.1: Ambulero's Product Pipeline	202
TABLE 15.2: BioCardia's Advanced Pipeline	219
TABLE 15.3: Bonus Biogroup's Product Pipeline	228
TABLE 15.4: BrainStorm's Product Pipeline	229
TABLE 15.5: CardioCell's Clinical Development	232
TABLE 15.6: Celltex's Clinical Trials	239
TABLE 15.7: Corestem's Product Pipeline	243
TABLE 15.8: Cynata's Product Pipeline	248
TABLE 15.9: Regulatory Proteins found in ExoFlo	253
TABLE 15.10: Hope's Clinical Trial Pipeline	265
TABLE 15.11: Growth Factors in XoGlo and XoGlo Plus	271
TABLE 15.12: Mesoblast's Late-Stage Clinical Pipeline	288
TABLE 15.13: Pluristem's Clinical Pipeline	304
TABLE 15.14: Regeneus' Product Pipeline	307
TABLE 15.15: Sentien's Product Pipeline	323
TABLE 15.16: Stemedica's Clinical Pipeline	327
TABLE 15.17: Stempeutics' Product Candidates in Clinical Trial	331



## About BioInformant:

As the first and only market research firm to specialize in the stem cell industry, BioInformant research has been cited by the Wall Street Journal, Nature Biotechnology, Xconomy, and Vogue Magazine.

Serving Fortune 500 companies that include Pfizer, GE Healthcare, and Goldman Sachs, BioInformant is your global leader in stem cell industry data.

To learn more, visit [BioInformant.com](http://BioInformant.com).

